Skip to main content
. 2020 Feb 13;14(4):829–845. doi: 10.1002/1878-0261.12638

Figure 4.

Figure 4

KO of BCAM by CRISPR/Cas9 system reduces GC cell metastasis in a mouse model. (A) The BCAM KO BGC‐823 cells were produced by the CRISPR/Cas9 system. The schematic diagram of the mutation in BCAM locus by CRISPR/Cas9 technique was shown. (B) Immunoblot analysis of the BCAM levels in wild‐type or BCAM KO BGC‐823 cells. (C‐G) MTT assay (C), colony‐forming growth assay (D), cell cycle analysis (E), transwell migration (F), and Matrigel invasion analysis (G) of wild‐type or BCAM KO BGC‐823 cells. The bar chart for cell cycle represents the percentage of cells in G0/G1, S, or G2/M phase. (H–J) Mice were intrasplenically injected with wild‐type or BCAM KO BGC‐823 cells and were subjected to liver metastasis analysis. Representative gross liver (H) and H&E‐stained liver sections (I) from mice were shown. Scar bars, 5 mm (H); Scar bars, 100 μm (I). The liver metastatic nodules were counted (J). Data are presented as the means ± SDs; ns, no significance. *P < 0.05. **P < 0.01. ***P < 0.001.